Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Cullinan Therapeutics is advancing multiple clinical programs with significant milestones expected throughout 2026, including initial data for CLN-978 in autoimmune diseases and updates on zipalertinib for oncology [1][2][3] Financial Overview - As of December 31, 2025, the company reported cash and investments totaling $439.0 million, providing a financial runway into 2029 [1][10] - Research and development expenses for Q4 2025 were $42.9 million, an increase from $40.5 million in Q4 2024, while total R&D expenses for the full year 2025 reached $187.4 million compared to $142.9 million in 2024 [5][11] - General and administrative expenses for Q4 2025 were $12.3 million, down from $14.6 million in Q4 2024, with full-year G&A expenses slightly increasing to $54.2 million from $54.0 million [5][11] - The net loss attributable to Cullinan was $50.7 million for Q4 2025, compared to $47.6 million in Q4 2024, and $219.9 million for the full year 2025, up from $167.4 million in 2024 [5][11] Clinical Development Highlights - CLN-978, a CD19xCD3 bispecific T cell engager, is set to provide initial data for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Q2 2026, with repeat dosing data expected in Q3 2026 [4] - Zipalertinib's rolling NDA submission has been completed, and the REZILIENT3 frontline study has been fully enrolled, with top-line results anticipated by the end of 2026 [1][3] - CLN-049, targeting acute myeloid leukemia (AML), is expected to advance to registrational development following promising clinical data and is set to initiate monotherapy dose expansion cohorts in Q2 2026 [4][8] Strategic Partnerships and Collaborations - The company is collaborating with Taiho Oncology on zipalertinib, which is nearing regulatory approval for treating EGFR ex20ins non-small cell lung cancer (NSCLC) [3][8] - Genrix Bio is enrolling a Phase 1 study for velinotamig in autoimmune diseases, with initial clinical data expected in Q4 2026, which Cullinan plans to leverage for global development [4]